Introduction
Mexiletine (MEX, 1-(2,6-dimethylphenoxy)-2-propanamine; Fig. 1 ) is classified as a Class Ib anti-arrhythmic group of drugs, according to Williams' classification, and is used for treating ventricular arrhythmias, similar to lidocaine.
1,2 MEX blocks the fast sodium channel, reducing the rate of depolarization of the cardiac action potential. The therapeutic range of the serum concentration of MEX is 0.5 -2.0 μg ml -1 , and when the concentration is greater than 2.0 μg ml -1 , it associates with high incidences of side effects, including hypotension, bradycardia, dizziness, blurred vision, tremors, and confusion. [3] [4] [5] Gastrointestinal and cardiovascular toxicities may also occur. 6 Since the intoxication range of the blood concentration is very close to the therapeutic range, monitoring of the serum concentration of MEX is necessary. In order to measure the MEX concentration in blood, sample preparation is necessary. Protein precipitation, solid-phase extraction, and liquid-liquid extraction are required for sample preparation. However, these pretreatments are complicated and take time. Hence, we employ a column-switching high-performance liquid chromatography (HPLC) so as to make a simpler method.
Various methods have been developed for the determination of MEX in biological fluids. Gas chromatographic (GC) methods require flame ionization detection, 7 electron-capture detection, 8, 9 or nitrogen-selective detection. 10 These detection methods are not sensitive enough to quantify the concentration of MEX. GC-mass spectrometry (GC-MS) 11, 12 including capillary GC-MS 13, 14 requires expensive instrumentation that is not always available in common laboratories. Li et al. reported a method that used liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the detection of MEX. 15 LC-MS/MS is sensitive and selective, but also expensive.
Several analytical HPLC methods utilizing UV [16] [17] [18] [19] [20] and fluorometric [21] [22] [23] [24] A sensitive HPLC method combined with a column-switching system and tris(bipyridine)ruthenium(III) electrogenerated chemiluminescence (ECL) detection has been developed for the quantitative determination of mexiletine (MEX). MEX was derivatized by divinylsulfone (DVS) and then measured. The optimum conditions for the derivatization reaction were 10 μL of sample solutions, 40 mM DVS (pH 8.0), a reaction temperature of 50 C, and a reaction time of 15 min. The derivatized samples were cleaned up by an on-line pretreatment column. Also, after column-switching to the analytical column, the derivatized MEX was separated and detected. The calibration curves of MEX in human control serum showed good linear regression (r = 0.9996) from 0.008 to 6.56 μg ml -1 . The detection limit of MEX was 0.008 μg ml -1 (S/N = 3). At a concentration of 2.0 μg ml -1 MEX, the relative standard deviation (n = 5) was 0.98%. In this method the concentration of MEX in human control serum was readily measured, and this method was successfully applied to the time courses of the concentration of MEX in rabbit plasma after intravenous administration. The proposed method involved a simple and minimum sample-preparation procedure and a short run time (<20 min). Therefore it can be applied to routine therapeutic monitoring and pharmacokinetic studies of MEX. with dansyl chloride for the analysis of MEX in rat plasma. 25 This reagent requires long reaction times and completion of the operation in dark. 25 Other derivatization reagents, such as ortho-phthalaldehyde, [26] [27] [28] 9,10-anthraquinone-2-sulfonyl chloride, 29 and 4-chloro-7-nitrobenzofurazan, 30, 31 have been applied for the analysis of MEX. However, these reagents require high reaction temperatures, 22, 30, 31 and complicated procedures. [26] [27] [28] [29] In general, chemiluminescence (CL) detection methods are known to be highly selective and sensitive. The tris(bipyridine)-ruthenium(II) (Ru(bpy)3
2+
, ECL reagent) electrogenerated chemiluminescence (ECL) system is useful for selective and sensitive determinations of aliphatic amines, such as tertiary amines. The oxidation-reduction reaction mechanism between Ru(bpy)3 2+ and tertiary amines (Scheme 1) has been investigated by many researchers. [32] [33] [34] This ECL reaction mechanism has been used for the determination of tertiary aliphatic 35, 36 and alicyclic amines, 37 amino acids, 38 and pharmaceutical products, such as erythromycin, 39 clindomycin, 40 and antihistamines. 41 This ECL reagent will, in general, react best with tertiary, then secondary, and finally primary amines. 35, 36 Aliphatic primary amines have only been detected at levels about 1000-times lower than those of tertiary amines, 35 and their detection is sometimes only possible after derivatization. Because MEX has a moiety of primary amine, the determination process of derivatization is essential. Lee and Nieman reported a method for the determination of dansyl chloride derivatized amino acids. 42 Niina et al. reported that primary and secondary amines are online derivatized by reactions with epichlorohydrin in a postcolumn reactor. 43 Morita and Konishi reported N-(3-aminopropyl)pyrrolidine (NAPP) as a reagent for the derivatization of primary amines. 44 However, NAPP reagents require a long reaction time. We previously reported the detection of primary amines using cycloaddition reactions with divinylsulfone (DVS). 45, 46 Since DVS as a derivatization reagent is rapidly reacted with primary amines, we decided to use it in this study.
In this paper, we discuss the use of a column-switching HPLC system for the determination of MEX using the cycloaddition reactions of primary amines with DVS, and the detection of derivatized-MEX (DVS-MEX) using Ru(bpy)3 3+ ECL. This method was also applied to determine the concentration of MEX in human control serum and rabbit plasma.
Experimental
Reagents and chemicals MEX, Ru(bpy)3Cl2 (powder), and DVS (97% pure) were obtained from Sigma-Aldrich (St. Louis, MO, USA) and used without further purification. Boric acid, sulfuric acid, and human control serum were obtained from Wako Pure Chemical Industries (Osaka, Japan). All other chemicals used were of analytical or HPLC grade.
Apparatus and single-column HPLC conditions
A single-column HPLC system combined with a Ru(bpy)3
2+
ECL detection system was used, following previously described methods. 45 Column-switching HPLC conditions Figure 2 is a schematic diagram of the column-switching HPLC system combined with the Ru(bpy)3 2+ ECL detection system. The HPLC system consisted of a LD-6A pump (pump 1) (Shimadzu, Kyoto, Japan), a 880-PU pump (pump 2) (Jasco, Tokyo, Japan), a uf-7002 PSSB2 pump (pump 3) (Uniflows, Tokyo, Japan), a Rheodyne 7125 sample injector with a sample volume of 100 μl (Rheodyne, Cotati, CA, USA), a COMET 2000A ECL detector (Comet, Kanagawa, Japan), and a C-R5A Chromatopac integrator (Shimadzu). The eluent and ECL reagent solutions were pumped through a Shodex Degas degasser (Showa Denko, Tokyo, Japan). The electrochemical oxidation mode was used for controlled-current electrolysis; the current was maintained at 80 μA. Column 1 was used as a Shim-pack MAYI-ODS column (10 × 4.6 mm; Shimadzu) for an on-line pretreatment. Column 2 was used as a Synergi 4u Fusion-RP 80A column (150 × 4.6 mm; Phenomenex, Torrance, CA, USA) for analysis. Eluent 1 was composed of 10 mM KH2PO4-CH3OH (65:35, v/v) and the flow rate was 0.5 ml min -1 . Eluent 2 was composed of 50 mM KH2PO4 buffer (pH 4.0)-CH3OH (40:60, v/v) and the flow rate was 1.0 ml min -1 . The ECL reagent solution was 0.3 mM Ru(bpy)3Cl2 in 10 mM H2SO4 at a flow rate of 0.45 ml min -1 . The analytical process of the column-switching HPLC was as follows:
Step 1 (0 -5.0 min, valve position A): Derivatized working, serum sample and rabbit plasma sample solutions were introduced into a pretreatment column (column 1). The column retained DVS-MEX and other endogenous constituents, and eliminated serum proteins and an unreacted derivatization reagent using eluent 1. The analytical column (column 2) was equilibrated using eluent 2 at this time.
Step 2 (5.0 -8.0 min, valve position B): When the valve position was changed to B, the DVS-MEX and other endogenous containing zone trapped in column 1 was transferred to column 2 by eluent 2.
Step 3 (8.0 min -next analysis, valve position A): The DVS-MEX and the endogenous-containing zone was separated by column 2 and eluent 2 when the valve position was switched ; ECL detector, 80 μA oxidation; injector, 100 μl.
back to position A. At the same time, column 1 was equilibrated using eluent 1 for the next analysis of DVS-MEX.
Solutions
A standard stock solution of MEX was prepared in water at a concentration of 0.5 mg ml -1 and stored at 4 C. A working solution was prepared by appropriately diluting the stock solution before use.
Derivatization procedure
The derivatization reagent solution (1 M, DVS) was prepared in methanol. A 5-ml mixture of 50 mM borate buffer (pH 8.0) and methanol (1:1, v/v) was added into a tube. Two hundred microliters of the 1 M DVS and 10 μl of the sample solutions (working, serum sample or rabbit plasma sample solution) were added to the tube, and then mixed with a vortex mixer. The reaction mixture was allowed to stand at 50 C for 15 min, and was then cooled to room temperature. A 20-μl aliquot of the reaction mixture was subsequently injected directly into the HPLC system.
Serum sample preparation and derivatization
The serum sample was prepared by adding the working solutions to the human control serum. A 1-ml mixture of 50 mM borate buffer (pH 8.0) and methanol (1:1, v/v) were mixed in a tube. Ten microliters of 1 M DVS methanol solution and 100 μl of the serum sample were added to the tube, and then mixed with a vortex mixer. The reaction mixture was allowed to stand at 50 C for 15 min, and then cooled to room temperature. The precipitate was removed by centrifugation at 5000 rpm for 5 min, and 100 μl of the supernatant was injected directly into the HPLC system.
Plasma concentration of MEX in rabbit after intravenous administration
MEX was intravenously administrated to a rabbit at a dose of 5 mg kg -1 . One milliliter of blood was collected 10, 30, 60, 90, 120, 180, and 300 min after administration of MEX. Plasma was immediately separated by centrifugation at 5000g for 15 min and stored at -20 C until being analyzed.
Results and Discussion
Derivatization DVS derivatization can be used to convert primary amines to alicyclic tertiary amines. The generation of ECL by the reaction of alicyclic tertiary amines with Ru(bpy)3 2+ has been previously reported. 34 The required conditions of this derivatization reaction, such as the reaction temperature, pH, DVS concentration, and reaction time, were examined, since the amounts of DVS-formed amines were proportional to the ECL intensities. The derivatization reaction of MEX with DVS is shown in Scheme 2. First, the effect of the borate buffer pH (range: pH 6 -10) on the amount of DVS-MEX formation was examined. The amount of DVS-MEX was shown to increase with increasing pH; maximum DVS-MEX amount occurred at pH 8, and then decreased with further increases in the pH (Fig. 3) . Next, the effects of the reaction time (range: 5 -50 min) and the reaction temperature (room temperature and 50 C) on the amount of DVS-MEX formation were examined. When the reaction temperature was 50 C, the rate of formation was constant within a reaction time of 5 -50 min. The rate of the DVS-MEX amount was accelerated by higher reaction temperatures (Fig. 4) . The reaction was completed within 5 min. The DVS-MEX was found to be stable for 50 min when stored at 50 C. Last, the effect of the DVS concentration (range: 0.2 -60 mM) on the amount of DVS-MEX formation was examined. The DVS-MEX amount was constant within a range of 10 -60 mM DVS (Fig. 5) . Therefore, these results indicate that the optimum derivatization conditions are 40 mM DVS at 50 C for a reaction time of 15 min. 
Effect of KH2PO4 concentration
The effect of the KH2PO4 concentration (eluent 2) within a range of 10 -100 mM on the ECL intensity was examined. The ECL intensity increased with increasing KH2PO4 concentration; the maximum ECL intensity occurred at 50 mM, and then the ECL intensity decreased with increasing KH2PO4 concentration (Fig. 6) . Therefore, a concentration of 50 mM KH2PO4 is considered to be optimum.
Method validation of single-column HPLC
A linear relationship between the injected amount of DVS-MEX and the ECL intensity was obtained from 0.08 to 8.25 μg ml -1 (r = 0.9997). The detection limit of DVS-MEX was determined to be 0.04 μg ml -1 with a signal-to-noise ratio of 3. The coefficient of variation (CV, n = 5) was 0.74% at a concentration of 2.0 μg ml -1 DVS-MEX. DVS-MEX was completely separated from the endogenous constituents, and no interfering peaks were detected during its retention time (Fig. 7) .
The analytical run time was within 10 min. When these optimized conditions were used for the HPLC determination of DVS-MEX in human control serum, DVS-MEX was not completely separated from the endogenous constituents. Thus, we examined the use of a column-switching HPLC system for the determination of DVS-MEX in human control serum.
Application
Analysis of MEX concentration in human control serum by column-switching HPLC. In HPLC analyses of drugs in human control serum, a pretreatment of the sample is essential due to complexities of the typical sample composition. In order to automate the on-line pretreatment of samples, extraction and column-switching were examined. Eluent 1 was eluted out with serum proteins and other hydrophilic components, trapping DVS-MEX to column 1. The selected eluent 1 was composed of 10 mM KH2PO4-CH3OH (65:35, v/v). Eluent 2 was eluted with DVS-MEX from column 1 and led to column 2. Eluent 2 consisted of 50 mM KH2PO4 buffer (pH 4.0)-CH3OH (40:60, v/v) should be selected. The effects of the pH of eluent 2 on the ECL intensity were examined within a range of pH 3 -7. Within the range of pH 3 -7, the ECL intensity remained constant. Therefore, pH 4 was selected for eluent 2. When these optimized conditions were used for the HPLC determination of DVS-MEX in human control serum, the recovery rate was 92%. Thus, in order to elevate the recovery rate, the effect of the DVS concentration within a range of 10 -100 mM on the rate of derivatization was investigated. The recovery rate of DVS-MEX was 100% at a DVS concentration of 100 mM. DVS-MEX was completely separated from the endogenous constituents, and no interfering peaks were detected during the retention time of MEX, and it took short run time (<20 min). A linear relationship between the injected amount of MEX in human control serum (range: 0.008 -6.56 μg ml -1 ) and the ECL intensity was obtained (r = 0.9996). The detection limit of MEX in human control serum was determined to be 0.008 μg ml -1 , with a signal-to-noise ratio of 3. The intra-and inter-assay CV for replicate analyses of MEX prepared in human control serum are given in Table 1 . The sample concentrations were 0.2, 0.5, and 2.0 μg ml -1 . The intra-assay CVs for each sample were 6.44, 2.16, and 0.98%, respectively (n = 5). The inter-assay CVs were 6.56, 4.93, and 4.69%, respectively (n = 3). DVS-MEX was completely separated from endogenous constituents, and no interfering peaks were detected during its retention time (Fig. 8) . Analysis of MEX concentration in rabbit plasma after intravenous administration by column-switching HPLC. Even when rabbit plasma was used, the calibration curve and the detection limit of MEX were similar to those of the human control serum. After intravenous administration, the time course of the concentration of MEX in rabbit plasma was rapidly reduced during the first HPLC conditions are the same as in Fig. 2 . Fig. 6 Effect of the KH2PO4 concentration of ECL intensity. 30 min, and then slowly declined during the remainder of the study (Fig. 9) . The distribution phase was observed for 30 min, and after 30 min the plasma concentration was 0.24 μg ml -1 . Several reports on the pharmacokinetics of MEX after intravenous administration have mentioned biphase elimination. 5, 21 Typical chromatograms of rabbit plasma are shown in Fig. 10 . This study is in general agreement with the results described by these reports.
Conclusions
The proposed method was able to determine the concentration of MEX in human control serum and rabbit plasma with high sensitivity and good validations. Calibration curves of MEX were linear over the concentration range of 0.008 -6.56 μg ml -1 in human control serum, which is as good as, or superior to, the results of previous reports. 21, [29] [30] [31] Furthermore, this method requires a small sample volume (100 μl), rapid and simple sample pretreatment, and rapid derivatization, 24, 26, 31 as well as a short run time (<20 min). The column-switching HPLC method involves the direct injection of human control serum and rabbit plasma samples onto the pretreatment column of an automated sample clean-up system. The present method is simpler and more economical than the other ones previously described. This method did not always need an internal standard. This is a possible method for the automated analysis of deproteinization and precolumn derivatization, and demonstrates the successful determination of serum MEX following a facile pretreatment procedure. Therefore, it can be applied to routine therapeutic monitoring and pharmacokinetic studies of MEX. 
